Abeona Will Include Early-stage MPS IIIA Patients in ABO-102 Gene Therapy Trial
Abeona Therapeutics is planning to expand its ongoing ABO-102 gene therapy Phase 1/2 trial to include patients with Sanfilippo syndrome type A (MPS IIIA) at earlier stages of the disease. “The encouraging data generated to date and our interactions with the U.S. Food and Drug Administration (FDA) and European…